ATR and neoplasm: Emerging evidence highlights resistance-associated alterations in CCNE1, CDK2, MYC [45, 46], FOXM1, ECT2 [47], CDC25A/B [48], and CDK8/CCNC [49], all of which may reduce tumor dependency on ATR signaling [50, 51].